These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36905319)

  • 1. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
    Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
    Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.
    Abbasi B; Shaw NM; Lui JL; Hakam N; Nabavizadeh B; Breyer BN
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5721. PubMed ID: 37909414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study.
    Chen G; Zhang L; Zhao ST; Huang H; Fu Z
    Expert Opin Drug Saf; 2024 Jul; 23(7):877-884. PubMed ID: 38739482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy.
    Furtado TP; Miranda EP; Deveci S; Jenkins L; Narus J; Nelson C; Mulhall JP
    J Sex Med; 2023 Dec; 21(1):29-32. PubMed ID: 37973393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
    Hsu JC; Tang DH; Lu CY
    Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
    Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
    Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
    Cui Y; Liu X; Shi L; Gao Z
    Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
    Lowe G; Costabile RA
    J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database.
    DE Nunzio C; Nacchia A; Grimaldi MC; Turchi B; Rovesti L; Franco A; Guarnotta G; Voglino O; Mancini E; Baldassarri V; Lombardo R; Cicione A; Tubaro A
    Minerva Urol Nephrol; 2024 Apr; 76(2):203-209. PubMed ID: 38498298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
    Mostafa T; Alghobary MF
    Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?
    Rezaee ME; Gross MS
    J Sex Med; 2020 Aug; 17(8):1579-1582. PubMed ID: 32622767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
    Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
    Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
    Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
    Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
    Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
    JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil.
    Wang Y; Zhao B; Yang H; Wan Z
    Andrology; 2024 May; 12(4):785-792. PubMed ID: 37724699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
    Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
    J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.